TY - JOUR
T1 - Overview and Recommendations for Prospective Multi-institutional Spatially Fractionated Radiation Therapy Clinical Trials
AU - Li, Heng
AU - Mayr, Nina A.
AU - Griffin, Robert J.
AU - Zhang, Hualin
AU - Pokhrel, Damodar
AU - Grams, Michael
AU - Penagaricano, Jose
AU - Chang, Sha
AU - Spraker, Matthew B.
AU - Kavanaugh, James
AU - Lin, Liyong
AU - Sheikh, Khadija
AU - Mossahebi, Sina
AU - Simone, Charles B.
AU - Roberge, David
AU - Snider, James W.
AU - Sabouri, Pouya
AU - Molineu, Andrea
AU - Xiao, Ying
AU - Benedict, Stanley H.
N1 - Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2024/7/1
Y1 - 2024/7/1
N2 - Purpose: The highly heterogeneous dose delivery of spatially fractionated radiation therapy (SFRT) is a profound departure from standard radiation planning and reporting approaches. Early SFRT studies have shown excellent clinical outcomes. However, prospective multi-institutional clinical trials of SFRT are still lacking. This NRG Oncology/American Association of Physicists in Medicine working group consensus aimed to develop recommendations on dosimetric planning, delivery, and SFRT dose reporting to address this current obstacle toward the design of SFRT clinical trials. Methods and Materials: Working groups consisting of radiation oncologists, radiobiologists, and medical physicists with expertise in SFRT were formed in NRG Oncology and the American Association of Physicists in Medicine to investigate the needs and barriers in SFRT clinical trials. Results: Upon reviewing the SFRT technologies and methods, this group identified challenges in several areas, including the availability of SFRT, the lack of treatment planning system support for SFRT, the lack of guidance in the physics and dosimetry of SFRT, the approximated radiobiological modeling of SFRT, and the prescription and combination of SFRT with conventional radiation therapy. Conclusions: Recognizing these challenges, the group further recommended several areas of improvement for the application of SFRT in cancer treatment, including the creation of clinical practice guidance documents, the improvement of treatment planning system support, the generation of treatment planning and dosimetric index reporting templates, and the development of better radiobiological models through preclinical studies and through conducting multi-institution clinical trials.
AB - Purpose: The highly heterogeneous dose delivery of spatially fractionated radiation therapy (SFRT) is a profound departure from standard radiation planning and reporting approaches. Early SFRT studies have shown excellent clinical outcomes. However, prospective multi-institutional clinical trials of SFRT are still lacking. This NRG Oncology/American Association of Physicists in Medicine working group consensus aimed to develop recommendations on dosimetric planning, delivery, and SFRT dose reporting to address this current obstacle toward the design of SFRT clinical trials. Methods and Materials: Working groups consisting of radiation oncologists, radiobiologists, and medical physicists with expertise in SFRT were formed in NRG Oncology and the American Association of Physicists in Medicine to investigate the needs and barriers in SFRT clinical trials. Results: Upon reviewing the SFRT technologies and methods, this group identified challenges in several areas, including the availability of SFRT, the lack of treatment planning system support for SFRT, the lack of guidance in the physics and dosimetry of SFRT, the approximated radiobiological modeling of SFRT, and the prescription and combination of SFRT with conventional radiation therapy. Conclusions: Recognizing these challenges, the group further recommended several areas of improvement for the application of SFRT in cancer treatment, including the creation of clinical practice guidance documents, the improvement of treatment planning system support, the generation of treatment planning and dosimetric index reporting templates, and the development of better radiobiological models through preclinical studies and through conducting multi-institution clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=85183545289&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85183545289&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2023.12.013
DO - 10.1016/j.ijrobp.2023.12.013
M3 - Review article
C2 - 38110104
AN - SCOPUS:85183545289
SN - 0360-3016
VL - 119
SP - 737
EP - 749
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 3
ER -